Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Novel approaches to advanced breast cancer: bevacizumab and lapatinibErica L Mayer, Nancy U Lin, Harold J Burstein
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast CancerSeth A Wander, Erica L Mayer, Harold J Burstein
Breast Cancer Research : BCR|September 25, 2007
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancerErica L Mayer, Lisa A Carey, Harold J Burstein
The Lancet. Oncology|March 3, 2022
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?Gabriele Antonarelli, Carmine Valenza, Erica L Mayer, et al.
NPJ Breast Cancer|March 23, 2023
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancerAlbert Grinshpun, Sara M Tolaney, Harold J Burstein, et al.
Progress in Cardiovascular Diseases|August 24, 2010
Cardiac toxicity from systemic cancer therapy: a comprehensive reviewGiuseppe Curigliano, Erica L Mayer, Harold J Burstein, et al.
American Journal of Perinatology|September 24, 2020
Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during PregnancyTaylor S Freret, Pedro Exman, Erica L Mayer, et al.
The Lancet. Oncology|February 3, 2022
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemicGeorg Pfeiler, Angela DeMichele, Amylou C Dueck, et al.
Journal of the National Cancer Institute|February 1, 2024
Association of N-terminal pro-brain natriuretic peptide with survival among US cancer survivorsChao Cao, Lin Yang, Anju Nohria, et al.
Oncology and Therapy|June 14, 2026
Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical EvidenceMiguel Martin, Alexandru Rosca, Alexandra Searles Vitko, et al.
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
Journal of the National Comprehensive Cancer Network : JNCCN|April 19, 2007
Novel approaches to advanced breast cancer: bevacizumab and lapatinibErica L Mayer, Nancy U Lin, Harold J Burstein
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast CancerSeth A Wander, Erica L Mayer, Harold J Burstein
Breast Cancer Research : BCR|September 25, 2007
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancerErica L Mayer, Lisa A Carey, Harold J Burstein
The Lancet. Oncology|March 3, 2022
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?Gabriele Antonarelli, Carmine Valenza, Erica L Mayer, et al.
NPJ Breast Cancer|March 23, 2023
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancerAlbert Grinshpun, Sara M Tolaney, Harold J Burstein, et al.
Progress in Cardiovascular Diseases|August 24, 2010
Cardiac toxicity from systemic cancer therapy: a comprehensive reviewGiuseppe Curigliano, Erica L Mayer, Harold J Burstein, et al.
American Journal of Perinatology|September 24, 2020
Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during PregnancyTaylor S Freret, Pedro Exman, Erica L Mayer, et al.
The Lancet. Oncology|February 3, 2022
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemicGeorg Pfeiler, Angela DeMichele, Amylou C Dueck, et al.
Journal of the National Cancer Institute|February 1, 2024
Association of N-terminal pro-brain natriuretic peptide with survival among US cancer survivorsChao Cao, Lin Yang, Anju Nohria, et al.
Oncology and Therapy|June 14, 2026
Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical EvidenceMiguel Martin, Alexandru Rosca, Alexandra Searles Vitko, et al.
Pageof 12